Subscribe

Eiken Chemical Co., Ltd. (4549.T)

JPY2,613.00 +62.00 (+2.43%)
JP JPX Healthcare Medical - Devices
Address 4-19-9 Taito 110-8408
Tokyo, JP
CEO Yuji Segawa
Website eiken.co.jp
IPO 2001-01-04
ISIN JP3160700005

Explore sections of this company profile

Description

Eiken Chemical Co., Ltd. is a Japanese manufacturer and distributor specializing in clinical diagnostic products and medical equipment. The company excels in developing diagnostic solutions for diverse medical fields, encompassing biochemical analysis, immunology, serology, dry chemical assays, and automated diagnostic systems. A significant offering is the OC-SENSOR, an automated immunochemical fecal test designed to identify gastrointestinal bleeding linked to conditions such as colorectal cancer, polyps, and diverticulitis. Its comprehensive product portfolio further includes real-time turbidimeters, temperature-controlled equipment, various amplification and fluorescence detection reagents for research applications, and general detection kits. Eiken Chemical also produces a variety of microbiology-related products, alongside additional immunological and serological reagents. Established in Tokyo, Japan, in 1939, the company initially operated as Nihon Eiyokagaku Co., Ltd. until its rebranding to Eiken Chemical Co., Ltd. in 1969.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY2,613.00 +62.00 (+2.43%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
179.2K
Beta
0.33
Float Shares
25.60M
Free Float %
77.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.25% -6.86% -17.63% +11.33% +21.79% +18.60% +28.15% +81.88% +39.77% +196.57% +307.14%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2,613.00
DCF (Unlevered) 2,662.93 +1.9%
DCF (Levered) 1,568.61 -40.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 0% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 1 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.94
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
3 / 5
Medium
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Devices: +11.2%
    +3.4% Q1'26: +6.3% (vs Q1'25)
  • ✓
    EPS growth Medical - Devices: +28.5%
    +75.0% ★ Q1'26: -113.1% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Devices: +30.9%
    +2.5% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Medical - Devices: +6.2%
    +7.0% ★ Q1'26: +1.3% (vs Q1'25)
  • ✗
    ROIC Medical - Devices: +3.3%
    +5.6% ★ Q1'26: +0.8% (vs Q1'25)
  • ✓
    Share dilution Medical - Devices: 0.0%
    -4.9% ★ Q1'26: -5.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    1.34× ★ Q1'26: 2.15× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.33) × ERP
WACC = 96% × Ke + 4% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 2,662.93 Current price: 2,613.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
2 Rev. Ana.
2 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
31.02B
est: 31.30B (-0.9%)
32.16B
est: 32.55B (-1.2%)
33.27B
est: 33.20B (+0.2%)
34.99B
est: 35.12B (-0.4%)
35.76B
est: 35.90B (-0.4%)
36.59B
est: 37.53B (-2.5%)
38.66B
est: 37.80B (+2.3%)
43.00B
est: 41.85B (+2.8%)
43.27B
est: 43.52B (-0.6%)
40.05B
est: 39.71B (+0.9%)
40.54B
est: 41.54B (-2.4%)
42.20B
42.20B – 42.20B
+1.6% YoY
43.56B
43.56B – 43.56B
+3.2% YoY
45.96B
45.96B – 45.96B
+5.5% YoY
48.21B
48.21B – 48.21B
+4.9% YoY
50.52B
50.52B – 50.52B
+4.8% YoY
EBITDA
4.07B
est: 6.11B (-33.3%)
4.96B
est: 6.35B (-21.9%)
5.53B
est: 6.48B (-14.6%)
5.13B
est: 6.85B (-25.1%)
6.20B
est: 7.00B (-11.5%)
6.36B
est: 7.32B (-13.2%)
8.58B
est: 7.37B (+16.4%)
10.55B
est: 8.16B (+29.2%)
9.73B
est: 8.49B (+14.6%)
5.85B
est: 7.02B (-16.7%)
5.56B
est: 7.34B (-24.2%)
7.46B
7.46B – 7.46B
+1.6% YoY
7.70B
7.70B – 7.70B
+3.2% YoY
8.12B
8.12B – 8.12B
+5.5% YoY
8.52B
8.52B – 8.52B
+4.9% YoY
8.93B
8.93B – 8.93B
+4.8% YoY
EBIT
2.82B
est: 4.46B (-36.9%)
3.53B
est: 4.64B (-24.0%)
3.85B
est: 4.73B (-18.6%)
3.48B
est: 5.01B (-30.5%)
4.66B
est: 5.12B (-9.0%)
4.73B
est: 5.35B (-11.7%)
6.87B
est: 5.39B (+27.5%)
8.49B
est: 5.97B (+42.2%)
7.61B
est: 6.21B (+22.6%)
3.52B
est: 4.80B (-26.7%)
3.01B
est: 5.03B (-40.2%)
5.11B
5.11B – 5.11B
+1.6% YoY
5.27B
5.27B – 5.27B
+3.2% YoY
5.56B
5.56B – 5.56B
+5.5% YoY
5.83B
5.83B – 5.83B
+4.9% YoY
6.11B
6.11B – 6.11B
+4.8% YoY
Net Income
2.10B
est: 1.89B (+10.9%)
2.43B
est: 2.16B (+12.5%)
2.92B
est: 2.67B (+9.3%)
2.61B
est: 2.27B (+14.8%)
3.45B
est: 2.94B (+17.1%)
3.54B
est: 3.17B (+11.4%)
5.04B
est: 4.42B (+14.1%)
6.22B
est: 5.63B (+10.4%)
5.74B
est: 5.32B (+7.8%)
2.63B
est: 2.14B (+22.9%)
2.23B
est: 2.92B (-23.8%)
3.52B
3.41B – 3.64B
+20.6% YoY
3.03B
3.03B – 3.03B
-14.0% YoY
3.54B
3.54B – 3.54B
+17.0% YoY
3.89B
3.89B – 3.89B
+9.9% YoY
4.24B
4.24B – 4.24B
+8.9% YoY
SGA
7.59B
est: 6.89B (+10.2%)
7.59B
est: 7.16B (+6.0%)
7.85B
est: 7.30B (+7.5%)
7.98B
est: 7.73B (+3.3%)
8.18B
est: 7.90B (+3.5%)
8.28B
est: 8.26B (+0.2%)
8.83B
est: 8.32B (+6.2%)
8.78B
est: 9.21B (-4.7%)
8.98B
est: 9.58B (-6.2%)
9.41B
est: 8.74B (+7.6%)
9.13B
est: 9.14B (-0.2%)
9.29B
9.29B – 9.29B
+1.6% YoY
9.59B
9.59B – 9.59B
+3.2% YoY
10.11B
10.11B – 10.11B
+5.5% YoY
10.61B
10.61B – 10.61B
+4.9% YoY
11.12B
11.12B – 11.12B
+4.8% YoY
EPS
57.57
est: 54.60 (+5.4%)
66.43
est: 62.28 (+6.7%)
79.69
est: 77.04 (+3.4%)
71.18
est: 65.51 (+8.7%)
93.61
est: 84.91 (+10.2%)
95.93
est: 91.58 (+4.7%)
136.63
est: 127.47 (+7.2%)
168.26
est: 162.43 (+3.6%)
155.17
est: 153.53 (+1.1%)
71.69
est: 65.03 (+10.2%)
64.82
est: 88.65 (-26.9%)
106.90
103.31 – 110.49
+20.6% YoY
91.90
91.90 – 91.90
-14.0% YoY
107.50
107.50 – 107.50
+17.0% YoY
118.10
118.10 – 118.10
+9.9% YoY
128.60
128.60 – 128.60
+8.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 A- 4/5 3/5 4/5 5/5 3/5 2/5 3/5
2026-05-11 A- 4/5 3/5 4/5 5/5 3/5 2/5 3/5
2026-05-08 A- 4/5 3/5 3/5 5/5 3/5 3/5 3/5
2026-05-07 A- 4/5 3/5 3/5 5/5 3/5 3/5 3/5
2026-05-01 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-30 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-28 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-27 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-24 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-23 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-22 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-21 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-20 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-17 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5
2026-04-16 B+ 3/5 3/5 3/5 5/5 2/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-441.91M
OE per share TTM
-11.23
Owner's Yield
-0.45%
Maintenance CapEx ratio
32.70%
Maint CapEx / Avg PPE
38.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 74 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 WisdomTree Japan SmallCap Dividend Fund DFJ 0.08% 290.2K 0.58%
2 State Street SPDR S&P International Small Cap ETF GWX 0.04% 354.7K 0.40%
3 iShares Healthcare Innovation UCITS ETF HEAL.L 0.04% 455.2K 0.40%
4 iShares MSCI Japan Small Cap UCITS ETF IDJP.L 0.04% 206.5K 0.58%
5 iShares MSCI Japan Small-Cap ETF SCJ 0.03% 75.4K 0.50%
6 WisdomTree Japan Hedged Equity Fund DXJ 0.02% 1.73M 0.48%
7 WisdomTree Japan Equity UCITS ETF - GBP Hedged DXJP.L 0.02% 235.3K 0.45%
8 WisdomTree Japan Equity UCITS ETF DXJ.L 0.02% 175.9K 0.48%
9 WisdomTree Japan Equity UCITS ETF - USD Hedged Acc DXJA.L 0.02% 175.9K 0.48%
10 WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc DXJD.SW 0.02% 217.2K 0.45%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
3.86M
Shares Outstanding
32.97M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hiroyasu Furuhashi Executive Officer & GM of Internal Audit Office — male
Katsunori Watanabe Exec Off, GM of Nogi Plant & Production Div and GM of Nasu Plant & Production Div — —
Keiichiro Yoshida Executive Officer and General Manager of Global Sales Division & Sales Headquarters — —
Michitoshi Doi Vice President, Executive Officer, GM, Production Headquarters, Chief Production Officer & CMSO — male
Norihiro Tomita Executive Officer and GM of Basic Research Laboratory & R&D Division — —
Satoshi Akaishi Executive Officer, GM of Domestic Sales Office & Sales Division and GM of Sales Admin Office — —
Tomohiro Kudo Executive Officer, GM, Business Management Headquarters, CFO & CHRO — —
Toshiyuki Tsuchitani Executive Officer, General Manager, Sales Headquarters & CMSO — —
Tsugunori Notomi Chairman — male
Yasuyoshi Mori Senior VP, Executive Officer, GM of R&D Headquarters, CTO & Director — —
Yuji Segawa President, CEO, COO & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices